Sarilumab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
DMC (Denmark), G-BA (Germany) and HAS (France), among others, recommended or restricted sarilumab, while NYE METODER (Norway) did not recommend it.
Assessment has run over 8.7 years, from 25 Feb 2017 at AWMSG (Wales) to 22 Oct 2025 at CIPM (Spain).
CIPM (Spain) changed its position: not recommended on 16 Jul 2025, recommended by 22 Oct 2025, after a resubmission.
No assessment is on file from PHARMAC (New Zealand), which is among the eight highest-volume agencies here.
Not every gap is a refusal: for sarilumab, 1 submission was never made and 2 were withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
7 distinct indication wordings are recorded for sarilumab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
1 of these 16 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess sarilumab, on 25 Feb 2017; CIPM (Spain) did not open a file until 16 Jul 2025 — an unusually long tail of 8.4 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 6 of 15 dated records fall in 2025 alone.
5 of the 10 agencies here assessed sarilumab more than once, G-BA (Germany) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
10 of the 18 agencies in this archive hold a record for sarilumab.
The full ledger for sarilumab reads 5 recommended, 2 no benefit, 2 not recommended and 2 restricted, with 5 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CIPM (Spain) | 22 Oct 2025 | Indicaciones terapéuticas autorizadas: Artritis reumatoide Kevzara en combinación con metotrexato (MTX) está indicado pa… | financed by the SNS · art. 92 a, c | source |
| G-BA (Germany) | 7 Aug 2025 | Kevzara — benefit assessment §35a | added benefit: not proven | source |
| SMC (Scotland) | 12 May 2025 | Treatment of polymyalgia rheumatica (PMR) in adult patients who have had an inadequate response to corticosteroids or who experience a relapse during corticosteroid taper… | not recommended | source |
| PBAC (Australia) | 2021 | Rheumatoid arthritis | Recommendation was rescinded by the PBAC with the support from the sponsor. | source |
| NYE METODER (Norway) | 26 May 2019 | Behandling av moderat til alvorlig aktiv revmatoid artritt (RA) | not introduced | source |
11 further decisions for sarilumab, across 8 agencies, are not shown here. They include the most recent record on file, 22 Oct 2025 from NICE (England); its outcome is in the subscriber dataset. They link to 11 further source documents.
Related molecules
- adalimumab — same ATC class L04A — Immunosuppressants
- upadacitinib — same ATC class L04A — Immunosuppressants
- secukinumab — same ATC class L04A — Immunosuppressants
- tocilizumab — same ATC class L04A — Immunosuppressants
- ustekinumab — same ATC class L04A — Immunosuppressants
- infliximab — same ATC class L04A — Immunosuppressants
Coverage: 16 decisions for sarilumab from 10 agencies, 2017 to 2025. Data to 7 Sep 2026. ATC class L04A — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.